Monday, October 26, 2026 · Edition updated 6:00 AM ETMON, OCT 26 editionNext edition in Next in --:--:--
Intelligence Verdict
AI startups · Drug discovery and biology

Bioptimus

“Building the World Model of Biology” Bioptimus, company-reported

  • Nonevaluation reported
  • —founding year not found
  • Has a model or API4 things shipped, by our search
The facts

Bioptimus at a glance.

Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.

Kind of company
Drug discovery and biologyAI that designs drugs, proteins and antibodies.
Based in
France
Founded
Not found in our sourcesBioptimus (company), Feb 20, 2024
Last closed-round valuation
No valuation reported
What it has shipped
Has a model or API
Founders
  • Jean-Philippe Vert: co-founder and CEO; Chief R&D Officer of Owkin and former Research Lead at Google Brain (as of Feb 2024) (Bioptimus (company), Feb 20, 2024)
Latest news

Released the Bioptimus SDK; earlier partnered with Cancer Research Horizons (Aug 2026). Oct 1, 2026

Bioptimus news page (company)

What it has built

Shipped, or not yet.

“Has a model or API” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.

open-source · Jul 11, 2024

H-Optimus-0, 1.1-billion-parameter open-source pathology foundation model

Source
product · May 6, 2025

H-Optimus-1 on AWS Marketplace

Source
model · Dec 17, 2025

M-Optimus multimodal model (early access)

Source
product · Oct 1, 2026

Bioptimus SDK

Source
2 rounds

Funding, as reported.

Every round we found, with the amount, valuation and investors as the source states them.

WhenRoundAmountValuationInvestors namedSource
Feb 20, 2024Seed$35 millionNot statedSofinnova Partners (lead), Bpifrance Large Venture, Frst, Cathay Innovation, Headline, Hummingbird, NJF Capital, Owkin, Top Harvest Capital, Xavier NielBioptimus (company)
Jan 14, 2025Not named (extension; total $76 million)$41 millionNot statedCathay Innovation (lead), Sofinnova Partners, Bpifrance Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Sunrise, Emmanuel Cassimatis, Thomas WolfBioptimus (company)
Our note

Worth knowing.

Our note: A pathology and multimodal biology model company rather than a drug developer, so no trial registry applies. Emerged from stealth 2024-02-20; founding year not stated. Company says H-Optimus-0 'consistently meets the performance or outperforms existing models' (company claim; no scores given). No 2025-2026 round beyond Jan 2025 found.